Literature DB >> 7520369

Therapeutic approaches to cystic fibrosis: memorandum from a joint WHO/ICF(M)A meeting.

.   

Abstract

Cystic fibrosis is one of the commonest genetic diseases among Caucasians and represents an important cause of suffering and death among children and adults. In the past two decades marked prolongation of the life of patients with cystic fibrosis has been achieved as the result of improved case-finding and an extensive regimen of therapies. More recently, a variety of new approaches to therapy have been developed or proposed as the result of advances in cell physiology and molecular biology. This article summarizes the presentations and discussions made at a joint WHO/ICF(M)A (International Cystic Fibrosis (Mucoviscidosis) Association) meeting, held in Washington, DC, on 14 October 1992, and reviews the current status of possible therapies for cystic fibrosis and their implications for treatment in various countries of the world.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520369      PMCID: PMC2486697     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  19 in total

1.  The development of psychiatric symptomatology in patients with cystic fibrosis.

Authors:  D A Pearson; A J Pumariega; D K Seilheimer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1991-03       Impact factor: 8.829

2.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

3.  Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

Authors:  S Shak; D J Capon; R Hellmiss; S A Marsters; C L Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer.

Authors:  M L Drumm; H A Pope; W H Cliff; J M Rommens; S A Marvin; L C Tsui; F S Collins; R A Frizzell; J M Wilson
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

5.  Nucleoside triphosphates are required to open the CFTR chloride channel.

Authors:  M P Anderson; H A Berger; D P Rich; R J Gregory; A E Smith; M J Welsh
Journal:  Cell       Date:  1991-11-15       Impact factor: 41.582

6.  A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis.

Authors:  M R Knowles; N L Church; W E Waltner; J R Yankaskas; P Gilligan; M King; L J Edwards; R W Helms; R C Boucher
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

7.  Mucus clearance with three chest physiotherapy regimes in cystic fibrosis: a comparison between postural drainage, PEP and physical exercise.

Authors:  L Lannefors; P Wollmer
Journal:  Eur Respir J       Date:  1992-06       Impact factor: 16.671

Review 8.  Gene therapy strategies for pulmonary disease.

Authors:  R G Crystal
Journal:  Am J Med       Date:  1992-06-22       Impact factor: 4.965

9.  Control of CFTR chloride conductance by ATP levels through non-hydrolytic binding.

Authors:  P M Quinton; M M Reddy
Journal:  Nature       Date:  1992-11-05       Impact factor: 49.962

10.  Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis.

Authors:  M R Knowles; L L Clarke; R C Boucher
Journal:  N Engl J Med       Date:  1991-08-22       Impact factor: 91.245

View more
  3 in total

Review 1.  Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

Authors:  Rainer Büscher; Hartmut Grasemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-10-11       Impact factor: 3.000

Review 2.  Drug management of noninfective complications of cystic fibrosis.

Authors:  I Sanchez; E Guiraldes
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 3.  Essential oils in the treatment of respiratory tract diseases highlighting their role in bacterial infections and their anti-inflammatory action: a review.

Authors:  Györgyi Horváth; Kamilla Ács
Journal:  Flavour Fragr J       Date:  2015-05-26       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.